All News
FDA Approves Rinvoq for Giant Cell Arteritis
Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib in the U.S. for use in rheumatology, gastroenterology, and dermatology.
Read Article
Metformin Effective in Osteoarthritis
d
MedPage Today
The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.
Read Article
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not Sxs. https://t.co/Xsju7JdEVE
Dr. John Cush RheumNow ( View Tweet)
Rheumatology: Believe It or Not (4/25/2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Should we believe the reviews and metanalyses?
https://t.co/pJFhcBkvjO https://t.co/9evGknrMSo
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush RheumNow ( View Tweet)
Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush RheumNow ( View Tweet)
US- Top Drug Rx Sales in 2024
Semaglutide $54 Billion
Tirzepatide $31.7 B
Adalimumab $28B
Apixaban $26 B
Empagliflozin $20.5 B
Pembrolizumab $18 B
Ustekinumab $17 B
Risankizumab $16 B
Dupilumab $15.6 B
Etanercept $10.1 B
Secukinumab $7.7 B
Immune globulin $7.1 B
Upadacitinib $7 https://t.co/Wjcu7LrTfC
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush RheumNow ( View Tweet)
U.S. healthcare pharmaceutical spending reached $805.9 billion in 2024, a 10.2% increase from 2023 https://t.co/Aq7utEJ8sK https://t.co/zgEPppe6Oe
Dr. John Cush RheumNow ( View Tweet)
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush RheumNow ( View Tweet)
Looking for the latest updates on treatments and disparities for patients with systemic lupus erythematosus and lupus nephritis?
Join us at AWIR 2025 to learn from Maria Dall’Era, MD, Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of https://t.co/QPyojkztCj
Association of Women in Rheumatology AWIRGROUP ( View Tweet)
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush RheumNow ( View Tweet)
Study of 104 RA-ILD pts found that (31.7%) RA-ILD patients were ANCA positive (29/31 were p-ANCA+). compared to ANCA neg, ANCA+ RA-ILD had more respiratory Sxs, ANA positivity, worse PFTs, more acute exacerbations of ILD, more bronchietasis & honeycombing https://t.co/vZODUW9tSX https://t.co/6WUbSoOyOm
Dr. John Cush RheumNow ( View Tweet)
Neglected adult PFAPA syndrome case ub 69 yoF mis-Dx as pharyngitis or lymphadenitis unresponsive to Abx. Could've been Rx w/ daily colchicine. (PFAPA = Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis) https://t.co/0Nx5uFlwSx https://t.co/5pv6qGI8IE
Links:
Dr. John Cush RheumNow ( View Tweet)
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/GhLtLqT0iS
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not https://t.co/VrLfiSGWGA
Dr. John Cush RheumNow ( View Tweet)
Vitamin D for Prevention of Disease
JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults. Guideline committee experts, included adult and pediatric endocrinology, internal medicine, obstetrics/gynecology, nutrition, and https://t.co/zi3CpE0DVN
Dr. John Cush RheumNow ( View Tweet)
